23.03.2023 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for .
RUBY-3, a basket study of povetacicept in autoimmune glomerulonephritis, has initiated patient enrollment; RUBY-4, a basket study of povetacicept in autoimmune cytopenias, targets initiation in Q2. | March 23, 2023
Alpine Immune Sciences (ALPN) Reports Q4, Provides Corporate Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Một góc nhìn khác về Ấn Độ baocantho.com.vn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from baocantho.com.vn Daily Mail and Mail on Sunday newspapers.